, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of viral diseases, inflammatory and fibrotic diseases, and oncology. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences
has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.
; Galapagos NV; Second Genome; Gadeta; Carna Biosciences Inc.
; Nurix Therapeutics, Inc.
; Kiniksa Pharmaceuticals
, Ltd.; Kyverna Therapeutics, Inc.
; Glympse Bio, Inc.
; Renown Institute for Health Innovation; Goldfinch Bio, Inc.
; Insitro, Inc.
; Novo Nordisk
A/S; Yuhan Corporation; Kite Pharma, Inc.
; oNKo-innate Pty
. Ltd.; and Roche Holding
AG. The company has partnership with Arcus Biosciences
to co-develop and co-commercialize next-generation cancer immunotherapies. Gilead Sciences
was founded in 1987 and is headquartered in Foster City, California.
On 07/11/20, Gilead announced its drug Remdesivir can reduce risk of death in COVID-19 patients.
On 07/10/20, Former FDA Commissioner Scott Gottlieb said Remdesivir data showed improved COVID-19 Recovery & Reduced Risk of Death by 62%.
The COVID-19 drug alone could be a huge revenue boom for Gilead into the future as many countries stockpile & use it.
On the Daily Chart
, it looks to me like a Pennant
has formed with a breakout coming, Bullish
The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.